Literature DB >> 7859852

Vaccination against hepatitis B: results of the analysis of 2000 population members in Croatia.

D Palmović1, J Crnjaković-Palmović.   

Abstract

The results of the analysis of vaccination against hepatitis B performed in 2,000 persons of high-risk groups in Croatia are described. All susceptible non-immunocompromised persons (HBsAg, anti-HBs, and anti-HBc negative) received either plasma-derived vaccine (HB-Vax MSD, 20 micrograms per dose) or recombinant HB vaccine (ENGERIX-B, SKB, 20 micrograms per dose) according to a 0.1 and 6-month schedule. Hemodialysis patients received four doses of HB vaccine (40 micrograms per dose). Seroconversion occurred in 98% of health care workers, 98.5% of family members of HBsAg chronic carriers, 98% of infants born to HBsAg carrier-mothers and 92% of hemodialysis patients. The percentage of poor-responders (titer of anti-BHs = 1-10 mIU/ml) for the groups was 2, 2, 8 and 20%, respectively, while low-responders (titer of anti-BHs = 10.1-100 mIU/ml) were 5, 4.5, 12 and 26%, respectively. A significant prevalence of non-responders, poor-responders and low-responders among male health care workers was noticed (p = 0.01, 0.026 and 0.002, respectively). Females significantly prevailed among excellent-responders (p = 0.0039). In hemodialysis patients, there were 8% non-responders, 19.5% poor-responders, and 26% low-responders. A significant difference between the percentage of good-responders (titer of anti-HBs = 101-1,000 mIU/ml) and excellent-responders (titer of anti-HBs over 1,000 mIU/ml) among health care workers and hemodialysis patients was documented (91% versus 46.5%, p < 0.0001). The combined passive-active immunization (hyperimmune hepatitis B globulin + hepatitis B vaccine) was effective in 98% of infants born to HBsAg carrier-mothers, and only one boy developed subclinical HBV infection (HBsAg and anti-HBc positive findings with normal ALT-values).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7859852     DOI: 10.1007/bf01719570

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  26 in total

1.  Immune response after vaccination with recombinant hepatitis surface antigen in maintenance hemodialysis patients and healthy controls.

Authors:  V Allegra; A Vasile; M Maschio; G Mengozzi
Journal:  Nephron       Date:  1992       Impact factor: 2.847

2.  Immunogenicity and efficacy of anti-hepatitis B vaccines in hemodialysis patients.

Authors:  P Dentico; A Volpe; R Buongiorno; N Maracchione; M Carbone; C Manno; F Proscia
Journal:  Nephron       Date:  1992       Impact factor: 2.847

3.  [Treatment and prevention of viral hepatitis].

Authors:  D Palmović
Journal:  Lijec Vjesn       Date:  1986 Feb-Mar

4.  Vaccination against viral hepatitis.

Authors:  F Deinhardt
Journal:  Infection       Date:  1982       Impact factor: 3.553

5.  Different hepatitis B vaccines.

Authors:  S Sherlock
Journal:  Scand J Infect Dis Suppl       Date:  1983

6.  Prevention of hepatitis B virus (HBV) infection in health-care workers after accidental exposure: a comparison of two prophylactic schedules.

Authors:  D Palmović; J Crnjaković-Palmović
Journal:  Infection       Date:  1993 Jan-Feb       Impact factor: 3.553

7.  [Vaccination against hepatitis B virus at the Lyon Pasteur Institute. A seven-year evaluation].

Authors:  V Fayol; A Cotisson; C Jullien; Y Rotivel; L Lery; G Ville
Journal:  Pathol Biol (Paris)       Date:  1991-09

8.  Analysis of a pregnancy-screening and neonatal-immunization program for hepatitis B in Hamilton, Ontario, Canada, 1977-1988.

Authors:  M A Chernesky; M A Blajchman; S Castriciano; J Basbaum; C Spiak; J B Mahony
Journal:  J Med Virol       Date:  1991-09       Impact factor: 2.327

9.  The newly licensed hepatitis B vaccine. Characteristics and indications for use.

Authors:  S Krugman
Journal:  JAMA       Date:  1982-04-09       Impact factor: 56.272

10.  Efficacy of a heat inactivated hepatitis B vaccine in male homosexuals: outcome of a placebo controlled double blind trial.

Authors:  R A Coutinho; N Lelie; P Albrecht-Van Lent; E E Reerink-Brongers; L Stoutjesdijk; P Dees; J Nivard; J Huisman; H W Reesink
Journal:  Br Med J (Clin Res Ed)       Date:  1983-04-23
View more
  4 in total

1.  Hepatitis B and HIV/AIDS in Zagreb: a district level analysis.

Authors:  G F Pyle; S Oreskovic; J Begovac; C Thompson
Journal:  Eur J Epidemiol       Date:  2000       Impact factor: 8.082

Review 2.  Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B.

Authors:  Gillian M Keating; Stuart Noble
Journal:  Drugs       Date:  2003       Impact factor: 9.546

3.  Surface protein mutations in chronic hepatitis B patients who received hepatitis B vaccine therapy.

Authors:  Maryam Daram; Ghodratollah Montazeri; Hadi Karimzadeh; Reza Malekzadeh; Mahmood Mahmoodi; Zahra Goodarzi; Hossein Keyvani; Shahram Mirmomen; Seyed Moayed Alavian; Michael Roggendorf; Seyed Mohammad Jazayeri
Journal:  Iran J Basic Med Sci       Date:  2014-09       Impact factor: 2.699

4.  Hepatitis B immunization in healthcare workers.

Authors:  Vishal Batra; Amitava Goswami; Sunil Dadhich; Dinesh Kothari; Narendra Bhargava
Journal:  Ann Gastroenterol       Date:  2015 Apr-Jun
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.